<DOC>
	<DOC>NCT01882504</DOC>
	<brief_summary>The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.</brief_summary>
	<brief_title>Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum</brief_title>
	<detailed_description />
	<mesh_term>Pyoderma Gangrenosum</mesh_term>
	<mesh_term>Pyoderma</mesh_term>
	<criteria>An established diagnosis of pyoderma gangrenosum Currently experiencing an inflammatory episode of pyoderma gangrenosum Contraceptive measures adequate to prevent pregnancy during the study Clinical evidence of acutely infected pyoderma gangrenosum History of allergic or anaphylactic reactions to monoclonal antibodies History of recurrent or chronic systemic infections Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breastfeeding Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pyoderma Gangrenosum</keyword>
	<keyword>Classic Pyoderma Gangrenosum</keyword>
	<keyword>Atypical Pyoderma Gangrenosum</keyword>
	<keyword>Peristomal Pyoderma Gangrenosum</keyword>
</DOC>